

02-14-01

PTO/SB/05 (08/00)

Approved for use through 09/30/00. OMB 0651-0032

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Please type a plus sign (+) inside this box →

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**UTILITY
PATENT APPLICATION
TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.

12636-898

10/21/2018
10/21/2018
10/21/2018

First Inventor or Application Identifier

Sands

Title

Injectable Pharmaceutical Compositions Comprising Microdroplets
Of A Camptothecin

Express Mail Label No.

EL 682 478 771 US

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO:
Commissioner for Patents
Box Patent Application
Washington, DC 20231

- Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original, and a duplicate for fee processing)
- Applicant claims small entity status. See 37 CFR 1.27.
- Specification *[Total Pages 64]*
 - Descriptive title of the Invention
 - Cross References to Related Applications
 - Statement Regarding Fed-Sponsored R&D
 - Reference to sequence listing, a table, or a computer program listing appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Detailed Description of the Drawings
 - Detailed Description
 - Claim(s)
- Drawing(s) (37CFR 1.152) *[Total Sheets 19]*
- Oath or Declaration *[Total Pages ____]*
 - Newly executed (original or copy)
 - Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 17 completed)
 - DELETION OF INVENTOR(S)**
Signed statement attaching deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).
- Application Data Sheet. See 37 CFR 1.76
- Microfiche Computer Program (*Appendix*)
- Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)
 - Computer Readable Copy
 - Paper Copy (identical to computer copy)
 - Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

- Assignment Papers (cover sheet & document(s))
- 37 CFR 3.73(b) Statement Power of Attorney
(when there is an assignee)
- English Translation Document (if applicable)
- Information Disclosure Copies of IDS Citations Statement (IDS) PTO-1449
- Preliminary Amendment
- Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
- Certified Copy of Priority Document(s)
(if foreign priority is claimed)
- Other: Statement Under 37 CFR 1.10

17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment:

 Continuation Divisional Continuation-in-part (CIP) of prior application No. _____

Prior application information: Examiner _____ Group/Art Unit: _____

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

18. CORRESPONDENCE ADDRESS Customer Number or Bar Code Label

021971

 Correspondence address below

(Insert Customer No. or Attach bar code label here)

NAME


ADDRESS

CITY

 STATE ZIP CODE

COUNTRY

 TELEPHONE FAX

Name (Print/Type)	David J. Weitz	Registration No. (Attorney/Agent)	38,362
Signature			
	Date <u>Feb. 12, 2001</u>		

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office,

PATENT
Attorney Docket No. 12636-898

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Sands, et al.) Group Art Unit: Not Yet Assigned
Application No. Not Yet Assigned) Examiner: Not Yet Assigned
Filed: Herewith)
For: INJECTABLE PHARMACEUTICAL)
COMPOSITION COMPRISING MICRO-)
DROPLETS OF A CAMPTOTHECIN)

STATEMENT UNDER 37 C.F.R. 1.10

Commissioner for Patents
Box Patent Application
Washington, D.C. 20231


Sir:

I hereby certify that the attached patent application is being deposited with sufficient postage with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10, Express Mail Label No. EL 682 478 771 US, on February 12, 2001, addressed to Box Patent Application, Commissioner for Patents, Washington, D.C. 20231.

Respectfully submitted,

WILSON SONSINI GOODRICH & ROSATI

By:



David J. Weitz
Registration No. 38,362

650 Page Mill Road
Palo Alto, California 94304
(650) 493-9300

February 12, 2001

This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):

- (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)
-- OR --
- (2) It is being filed within 3 months of entry of a national stage
-- OR --
- (3) It is being filed before the mail date of the first Office Action on the merits
-- OR --
- (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:

- a certification as specified in §1.97(e) is provided below; or
- a fee of \$240.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.

37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:

- A. a certification as specified in §1.97(e) is completed below; and
- B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; and
- C. a fee of \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.

Fee Authorization. The Commissioner is hereby authorized to charge the above-referenced fees of \$0.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 23-2415 (Docket No. 12636-898).

Respectfully submitted,

WILSON SONSINI GOODRICH & ROSATI

By: David J. Weitz
David J. Weitz, Reg. No. 383362

Dated: Feb. 12, 2001

650 Page Mill Road
Palo Alto, CA 94304-1505
(650)493-9300
Customer No. 021971